financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Buy Opinion On Shares Of Micron Technology, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Buy Opinion On Shares Of Micron Technology, Inc.
Mar 18, 2024 9:51 PM

12:25 AM EDT, 03/19/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We boost our 12-month target to $110 from $94, on a P/E of 12.6x our CY 25 EPS view, near MU's long-term historical average. We narrow our FY 24 (Aug.) loss per share estimate to $0.20 from $0.51 and raise FY 25's EPS to $7.28 from $6.14. Ahead of Feb-Q results set to be released on 3/20, we see loss per share of $0.25 on $5.3B in revenue (implies +45% growth), as we think the recovery in memory is gaining momentum. We think MU remains well-positioned, given its strong DRAM exposure (over 70% of revenue), which is seeing a more favorable pricing landscape. We also like MU's greater emphasis on DRAM servers that are higher priced (higher margin) as well as upside that can be seen from High Bandwidth Memory (HBM), as MU is tethered to Nvidia's H200 (ramping in CQ2; B200 later this year powers even more HBM memory). Given content gain potential and increasing shift towards higher-value AI servers, we think MU's multiple could expand versus historical levels (not in our analysis), which could offer upside ahead.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Oct 8, 2025
01:40 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Pfizer Inc. (PFE 26 ****) and the U.S. government struck the first Most Favored Nation (MFN) drug pricing deal to lower drug prices in the U.S., we see policy...
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Oct 8, 2025
02:20 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We are lowering our opinion on the Real Estate sector to underweight given its vulnerability to potential disappointment if Fed rate cuts prove less aggressive than market expectations, combined with...
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Oct 9, 2025
01:45 PM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target of $170, based on a 2026 P/E of 20.2x, a justified discount to PEP's five-year mean forward P/E of 23.0x. We maintain our adjusted EPS...
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Oct 9, 2025
10:15 AM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $350, based on a 2026 P/E of 30x, a justified discount to RACE's 10-year average forward P/E multiple of 40x. Our adjusted EPS estimates...
Copyright 2023-2025 - www.financetom.com All Rights Reserved